SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

(2013) S. H. Petersdorf et al.   BLOOD

Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin

(2013) Roland Walter   Frontiers in Bioscience-Landmark

Acute myeloid leukemia stem cells and CD33-targeted immunotherapy

(2012) R. B. Walter et al.   BLOOD

Cancer statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Small molecule drugs – optimizing DNA damaging agent-based therapeutics

(2012) John A Hartley et al.   CURRENT OPINION IN PHARMACOLOGY

Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia

(2012) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

(2012) Sylvie Castaigne et al.   LANCET

SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma

(2011) R.-O. Casasnovas et al.   BLOOD

What Happened to Anti-CD33 Therapy for Acute Myeloid Leukemia?

(2011) Joseph G. Jurcic   Current Hematologic Malignancy Reports

Sequential Cytarabine and  -Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for Acute Myeloid Leukemia

(2010) T. L. Rosenblat et al.   CLINICAL CANCER RESEARCH

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML)

(2008) Ruoping Tang et al.   BMC CANCER